Fixed lab capacity
Labs carry large fixed costs in analyzers, staff and courier networks, so volume and utilization drive cost per test.
DIAGNOSTICS / STRATEGY + OPERATIONS
Test volume only pays when reimbursement, collections and lab cost line up
Diagnostics companies run clinical laboratories and develop in vitro diagnostic tests, instruments and reagents, from routine chemistry to molecular, genetic and pathology testing. Labs earn per-test reimbursement from Medicare, commercial payers and health systems, while IVD makers sell instruments and recurring reagents, so profit depends on volume, test mix, reimbursement and cost per test.
P&L OPERATING MODEL
See how commercial and operating decisions move the P&L.
Select a sector and switch between the profit bridge and the underlying cost structure. The baseline is indexed to revenue so the economics remain comparable.
INDUSTRY P&L BRIDGEDIAGNOSTICS / REVENUE INDEXED TO 100
REVENUE INDEX100.0 → 104.0Commercial growth case
OPERATING PROFIT18.0 → 25.4+7.4 points
MARGIN18.0% → 24.4%Combined opportunity case
18.0Baseline profit
+4.0Revenue growth
+1.0Lab labor
+0.8Reagents & consumables
+0.5Specimen logistics
+0.6Billing & revenue cycle
+0.5Sales & G&A
25.4With Aryo profit
REVENUEPrice, mix, retention, channel, product, and market focus
COSTProcurement, labor, throughput, footprint, complexity, and overhead
DATACompany actuals, industry benchmarks, operating signals, and measured deltas
HOW THE BUSINESS WORKS
How diagnostics companies make money.
The revenue streams and structural traits that decide where profit is made and lost in this sector.
Revenue model
- Per-test reimbursement from Medicare, Medicaid and commercial payers
- Outreach and reference testing for hospitals and physician groups
- Instrument placements with recurring reagent and consumable revenue
- Biopharma services such as companion diagnostics and clinical trial testing
Reimbursement uncertainty
Coverage and pricing for new molecular and genetic tests depend on payer policy and coding decisions that can take years.
Collection risk
A meaningful share of billed tests goes unpaid because of denials, missing order information and patient balances.
Reagent pull-through
IVD makers earn most of their profit from reagents on installed instruments, so placements and test menu breadth matter.
WHAT TO WATCH
The measures and pressures that matter now.
Five numbers management should review every month, and what is changing in the sector.
- 1
Cost per requisition
Captures lab efficiency including specimen collection, transport and processing.
- 2
Revenue per requisition
Shows test mix and reimbursement level.
- 3
Collection rate on billed tests
Indicates how much testing actually turns into cash.
- 4
Turnaround time
Drives physician and hospital satisfaction and competitive position.
- 5
Analyzer utilization
Shows when to add, consolidate or retire testing platforms.
Pressures right now
- A federal court vacated FDA’s rule on laboratory-developed tests in 2025, removing one compliance burden but leaving future oversight unclear.
- Scheduled Medicare clinical lab fee schedule cuts under PAMA keep being delayed rather than resolved, which complicates planning.
- Coverage decisions for genomic, minimal residual disease and other advanced tests remain slow and uneven across payers.
- Health systems are re-evaluating their outreach lab businesses, creating acquisition opportunities and new competition.
WHERE THE VALUE IS
Where diagnostics companies find the most value.
The changes that usually move the P&L most in this sector, and the service that delivers each one.
Revenue cycle
Capture complete patient, insurance and diagnosis data at order entry, and work denials by root cause.
Workflow automation & AI agentsLab productivity
Automate pre-analytics and redesign shifts around when specimens actually arrive.
Process & productivity improvementMarket access
Build the clinical utility and economic evidence payers need to cover and price new tests.
Go-to-market & channel strategyOutreach lab acquisitions
Evaluate and integrate hospital outreach programs and smaller labs to fill existing capacity.
M&A strategy & due diligenceQuestions leaders in diagnostics should be able to answer
- What share of the tests we run are we actually paid for, and why are the rest unpaid?
- Where is our cost per requisition highest, and how much of that is volume versus process?
- Which new tests have a credible path to coverage, and how long can we fund them until then?
SECTORS IN THIS INDUSTRY
One industry architecture, adapted to the operating context.
The same strategic question behaves differently by customer, product, asset, regulation, channel, and business model.